A new study found that a gene recently recognized as a biomarker for Alzheimer’s disease is actually a cause of it, due to its previously unknown secondary function that triggers a pathway that disrupts how cells in the brain turn genes on and off.
access_time Embargo lifts in 2 days
This news release is embargoed until 30-Apr-2025 4:00 PM EDT
Released to reporters: 24-Apr-2025 9:10 PM EDT
A reporter's PressPass is required to
access this story until the embargo expires on 30-Apr-2025 4:00 PM EDT
The 鶹ý PressPass gives verified journalists access to embargoed stories.
Please log in to complete a presspass application.
If you have not yet registered, please Register. When you
fill out the registration form, please identify yourself as a reporter in order to
advance to the presspass application form.
In a landmark clinical trial, coordinated by the Alzheimer's Disease Cooperative Study at UC San Diego, people at risk for Alzheimer's who exercised at low or moderate-high intensity showed less cognitive decline when compared to those receiving usual care.
Temple University, Philadelphia - Brain tissue analysis of an animal model reveals the potential role of immune system dysfunction in the onset and progression of Alzheimer’s Disease (AD).
Having a larger waistline, high blood pressure and other risk factors that make up metabolic syndrome is associated with an increased risk of young-onset dementia, according to a study published on April 23, 2025, online in Neurology®, the medical journal of the American Academy of Neurology.
Researchers have developed an AI-driven machine learning model that can predict post-concussion injury risk in athletes with 95% accuracy, analyzing more than 100 variables. The machine's algorithm has potential beyond sports, including the ability to predict fall risk in patients with Parkinson’s disease.
How do we learn new things? Neurobiologists using cutting-edge visualization techniques have revealed how changes across our synapses and neurons unfold. The findings depict how information is processed in our brain’s circuitry, offering insights for neurological disorders and brain-like AI systems.
Clinical trial results indicate that people living with primary progressive aphasia (PPA) and their communication partners benefit from remote speech language therapy.
A new study has found important clues about the roles age, sex, hormonal changes and genetics play in how certain biomarkers for dementia are expressed in the blood, according to a study published on April 16, 2025, online in Neurology®, the medical journal of the American Academy of Neurology.
The Focused Ultrasound Foundation today announced a historic achievement for the field of noninvasive medicine: more than one million patients worldwide have now been treated with focused ultrasound.
While some studies have suggested that having a mother with Alzheimer’s disease may put you more at risk of developing the disease, a new study finds that having a father with the disease may be tied to a greater spread of the tau protein in the brain that is a sign of the disease, according to a study published on April 9, 2025, online in Neurology®, the medical journal of the American Academy of Neurology.
New research finds that older adults whose children did not graduate from high school experienced early cognitive decline, while older parents whose children completed college were less likely to experience the onset of dementia.
Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced the publication of a special themed section of research papers that provide crucial insights into the complex health economics of Alzheimer's disease and related dementias (ADRD), offering a roadmap for future research and policy as the aging population grows and novel treatments emerge.
Researchers have introduced improved cognitive tests to assess dementia in older Africans, part of the HAALSI-HCAP study in rural South Africa. These tools, tailored for local contexts, enhance global ageing research and could inform a national survey. With dementia rates rising, findings will aid prevention and policy.
يواجه أغلب مرضى داء الزهايمر والخَرَف المرتبط بداء الزهايمر الظهور والتقدم التدريجين للأعراض الإدراكية، مما يسبب التدهور على مدى سنوات أو عقود. إلا أنه في مجموعة فرعية صغيرة من المرضى تبدأ الأعراض سريعًا، مؤديةً إلى الإصابة بالخَرَف في غضون سنة واحدة والعجز الكامل خلال سنتين من بداية ظهور الأعراض. وتطمح دراسة جديدة تُجرى في مايو كلينك إلى تحديد سبب إصابة مرضى داء الزهايمر والخَرَف المرتبط بداء الزهايمر بهذا الخَرَف سريع التقدم.
A maioria dos pacientes com doença de Alzheimer (DA) e demências relacionadas à doença de Alzheimer (DRDA) experimenta o início gradual e a progressão dos sintomas cognitivos, levando-os ao declínio ao longo dos anos ou das décadas. No entanto, em um pequeno subconjunto de pacientes, os sintomas começam rapidamente, levando à demência dentro de um ano e à incapacidade total dentro de dois anos após o início dos sintomas. Um novo estudo na Mayo Clinic tem como objetivo determinar por que pacientes com a doença de Alzheimer e DRDA desenvolvem essa demência rapidamente progressiva (DRP).
La mayoría de los pacientes con enfermedad de Alzheimer (EA) y enfermedad de alzheimer y las demencias relacionadas (DRDA, por sus siglas en inglés) experimenta el inicio gradual y la progresión de los síntomas cognitivos, lo que los lleva al deterioro a lo largo de los años o décadas. Sin embargo, en un pequeño subconjunto de pacientes, los síntomas comienzan rápidamente, lo que lleva a la demencia dentro de un año y a la discapacidad total dentro de los dos años posteriores al inicio de los síntomas. Un nuevo estudio en Mayo Clinic tiene como objetivo determinar por qué los pacientes con la enfermedad de Alzheimer y DRDA desarrollan esta demencia rápidamente progresiva (DRP).
Most patients with Alzheimer's disease and Alzheimer's Disease Related Dementias (ADRD) experience the gradual onset and progression of cognitive symptoms, leading to decline over years or decades. However, in a small subset of patients, symptoms begin rapidly, leading to dementia within one year and complete incapacitation within two years of symptom onset.